Lycia’s IPO Is Built Around an IgE-Removing Strategy for Food Allergy
Lycia Therapeutics is heading to the public markets with a capital plan built around one central clinical bet: a protein degrader that does more than block IgE. The South San Francisco company is seeking up to $227.8 million in net proceeds from an initial public offering that would finance phase 2 development of LCA-0061, its lead catalytic lysosomal targeting chimera, or cataLYTAC, for food allergy and other allergic diseases.
The distinction is straightforward at the bedside. Current IgE-targeted therapies can blunt signaling, but they do not eliminate the immunoglobulin itself. Lycia is pushing a different biological concept, one designed to remove extracellular IgE from circulation by directing it into lysosomal degradation. In allergic disease, where IgE sits near the center of mast cell and basophil activation, a true reduction in the total pool of circulating IgE could matter in patients whose disease burden is tied to persistent sensitization.
The IPO filing lays out a company built around that premise. Lycia plans to sell 14.7 million shares at $16 to $18 apiece, with gross proceeds rising further if underwriters exercise their option to buy an additional 2.2 million shares. At the midpoint of the range, the company expects net proceeds of $227.8 million, or $262.7 million with the full greenshoe. The financing is not being raised as abstract corporate firepower; it is tied to concrete clinical programs, with roughly $80 million earmarked to advance LCA-0061 into phase 2.
A Phase 2 Bet on Deeper IgE Reduction
LCA-0061 is intended to treat food allergy by depleting IgE rather than merely inhibiting its effects. Lycia’s filing positions that mechanism against existing therapies such as Novartis and Genentech’s Xolair, which has benefited patients with food allergy but remains limited by weight-based dosing and a ceiling imposed by very high circulating IgE levels. Those practical constraints matter in a disease where dosing complexity can slow uptake and where baseline IgE burden may influence how much clinical effect a blocker can deliver.
The biological argument for a degrader is different. By targeting extracellular IgE for lysosomal breakdown, LCA-0061 is built to drive down both total and free IgE. If that effect holds in larger studies, it could translate into less allergic reactivity over time, not simply temporary receptor blockade. In a condition defined by unpredictable exposure and potentially severe reactions, a durable reduction in the underlying antibody pool is the kind of mechanism clinicians can understand immediately, even before hard outcomes are fully defined.
Lycia says preliminary phase 1 findings support that theory. The ongoing early study has shown a rapid, deep, and sustained reduction in total and free IgE, with no safety signals or dose-limiting toxicities observed so far. Those are early signals, not proof of clinical benefit, but they are the kind of pharmacodynamic readout that matters for a first-in-class degrader. If the antibody can be cleared efficiently without obvious toxicity, it gives the program a rational path into midstage testing.
One sentence captures the stakes: this program is trying to convert an allergic mediator from something to block into something to remove.
Why Lycia Is Funding a Second Food Allergy Candidate Too
A separate $70 million slice of the IPO proceeds is slated for LCA-0062, described as a fast-follower cataLYTAC degrader for food allergy. Lycia says the second program is intended to provide “additional flexibility in dosing and duration of response” relative to LCA-0061. In practice, that suggests the company sees enough promise in the overall platform to hedge the lead candidate with a follow-on molecule that may be easier to administer, last longer, or fit different clinical use patterns.
That strategy fits the current allergy field, where treatment durability and dosing burden can determine whether a therapy works in real life as well as it does on paper. Food allergy care often requires long-term management, repeated counseling, and careful patient adherence. A therapy that reduces the need for frequent re-dosing would not simply be more convenient; it could broaden the group of patients willing to pursue biologic treatment in the first place.
Lycia has not yet disclosed phase 2 data for either food allergy candidate, so the real clinical question remains how the pharmacology will translate into tolerated, sustained suppression of IgE in a broader population. The initial signal from phase 1 is encouraging, but allergy therapeutics have a long history of looking strong in biomarker readouts before clinical utility becomes clear. The next study will have to show whether profound IgE lowering leads to meaningful disease control and whether that effect can be maintained without safety tradeoffs.
Graves’ Disease Adds a Second Immunology Test Case
Food allergy is not the only immunologic indication in Lycia’s portfolio. The company says it needs about $90 million to move LCA-0321, a LYTAC degrader, into a midstage study for Graves’ disease. That program is designed to selectively degrade TRAbs, the pathogenic drivers of Graves’ disease. The clinical logic is familiar: remove the mediator that drives autoimmunity at its source rather than blocking downstream consequences of antibody activity.
Graves’ disease offers a different proving ground for the same general principle. If targeted degradation can cleanly reduce pathogenic antibodies in one immune-mediated disease, the platform could become relevant across a wider range of autoimmune and inflammatory disorders. For now, though, the public offering is anchored by the food allergy program, where the comparison with existing IgE therapy is direct and clinically intuitive.
Cash Runway and the Shape of the Platform
Lycia entered the second half of the year with $148.1 million in cash after a funding sequence that included a $50 million launch in 2020, a $70 million Series B in 2021, a $106.6 million Series C in 2024, and a $75 million raise in June. The company’s workforce stands at 31 full-time employees, and the IPO is the next step in a financing trajectory that has been steadily pushing the platform toward human efficacy testing.
The market will now be asked to price a specific scientific proposition: whether protein degradation can outperform simple blockade in allergic disease. The answer will depend on whether IgE removal produces the kind of depth, durability, and safety profile suggested by early data, and whether phase 2 can convert a mechanistic advantage into a clinically meaningful one. For Lycia, the IPO is not just a capital event. It is a request to fund the next proof point for a therapy that aims to clear the allergic driver out of circulation rather than merely quiet it.